Brain fog became one of the defining and most feared features of long COVID, the syndrome in which fatigue, breathlessness and cognitive complaints persist for months after the acute illness has cleared. The cognitive dimension is broad but specific: it typically involves attention, memory and executive function, the higher-order machinery the brain uses to plan, focus, juggle competing demands and restrain impulses. Earlier variants of SARS-CoV-2, including the original strain, Alpha and Delta, were repeatedly linked to persistent cognitive deficits in survivors, raising fears that infection might scar the mind as deeply as the lungs. Omicron changed the calculus. The variant generally causes less severe disease than its predecessors, yet it infected an enormous share of the world’s population, including vast numbers of older adults. That shift left scientists with an urgent, unresolved question: would a milder variant still leave a cognitive mark, and if it did, would the deficits persist, improve with time, or — the darkest possibility — keep worsening, particularly in older people whose brains carry less reserve to absorb an insult?

To find out, a research team led by Professor Yan Wan and Professor Bo Hu of the Department of Neurology at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, followed patients hospitalized with COVID-19 during the Omicron-predominant period from December 2022 to March 2023 across nine hospitals in China. In total, 3,419 patients were enrolled in the two-year multicenter cohort study. Because gathering thousands of recovering patients for laboratory testing is impractical, the researchers assessed cognition by telephone at six months and two years after infection using two complementary, validated instruments. The Telephone Interview of Cognitive Status-40, or TICS-40, is a structured cognitive screen that probes orientation, attention, calculation, memory registration, delayed recall, learning ability and language-based reasoning, producing a numerical score that can be tracked over time. The Informant Questionnaire on Cognitive Decline in the Elderly, or IQCODE, adds a different lens by asking a relative or close contact whether the person’s memory and everyday thinking have actually deteriorated in daily life. Among the enrolled patients, 2,087 survivors completed both the six-month and two-year assessments, and their paired scores allowed the team to assign every participant to one of four cognitive trajectories: stable, reversible decline, non-progressive decline or progressive decline.

The results sketch a portrait of unexpected resilience. Two years after discharge, 67.1 percent of participants had maintained stable cognitive function throughout the entire observation period. Another 22.0 percent had experienced reversible cognitive decline: their scores sagged in the first six months and then climbed back by the two-year visit. Irreversible decline, meaning deficits that never recovered during the study window, affected 10.8 percent of survivors. That group divided into two starkly different fates. Some 7.2 percent showed non-progressive decline, a fixed deficit that neither improved nor worsened, while 3.6 percent — the smallest and most worrying slice of the cohort — followed a progressive trajectory of continuing deterioration. Put simply, nearly nine in ten hospitalized Omicron survivors were either cognitively stable or firmly on a path to recovery two years after their illness, a proportion that defies the grim expectations set by earlier variants of the virus.

The raw scores behind those trajectories reveal what recovery actually looks like in the brain. Among patients whose decline reversed, average TICS-40 scores rose by three points, from 21.00 at six months to 24.00 at two years — a meaningful climb on an instrument where each point reflects real cognitive performance. Crucially, the improvement was not diffuse but strikingly domain-specific. Patients regained ground in attention and calculation, delayed recall, memory registration, learning ability and executive function. Registration, the capacity to hold new information in mind for its first few seconds, and delayed recall, the ability to retrieve that information minutes later, are the bedrock of everyday memory: remembering a shopping list, an appointment or a familiar name. Attention and calculation, often tested by counting backward by sevens, underpin everything from managing household finances to following a conversation in a noisy room. The progressive group moved in precisely the opposite direction, shedding four points, from 17.00 to 13.00, with deterioration concentrated in attention and calculation, delayed recall and registration — the very domains that rebound in others, and exactly the skills that determine whether an older adult can continue living independently.

Just as important as who recovered, however, is who did not — and the risk factors form a coherent biological picture. Being 60 years or older carried more than a fourfold increase in the odds of progressive decline, consistent with the aging brain’s thinner cognitive reserves and decades of accumulated vascular wear. Reinfection stood out as perhaps the most consequential and modifiable red flag: each additional SARS-CoV-2 infection more than doubled the odds of a progressive course, hinting that repeated viral exposures may compound injury to the brain’s blood vessels and immune environment. Severe COVID-19, longer hospitalization, hypertension and the presence of white matter lesions — bright scars visible on brain imaging that signal damage to the delicate wiring of the nervous system and the small vessels that feed it — were each independently associated with progressive decline. Taken together, the profile suggests that patients fared worst when an aging or previously injured cerebral microvasculature met the systemic inflammation, oxygen deprivation and immune storm that accompany severe or repeated infection.

Two forces pushed the odds in the opposite direction, toward protection. Every additional year of education lowered the risk, in line with the well-established concept of cognitive reserve — the idea that education, occupational complexity and lifelong mental engagement build denser, more flexible neural networks that can absorb injury before symptoms ever surface. And every additional dose of vaccine also shifted a patient’s trajectory away from progressive decline, an observation with obvious public health weight. Vaccination is known to blunt viral replication, reduce disease severity and lower the risk of reinfection, any of which could spare the brain both direct viral insult and the collateral damage of systemic inflammation. The researchers suggest these same mechanisms may help explain why Omicron-era cohorts, in whom immunity from vaccination and prior infection is widespread, appear to fare cognitively better than patients infected by the harsher variants that dominated the pandemic’s first years.

“Our findings indicate that cognitive decline after Omicron infection is not necessarily permanent,” said Professor Wan. “The substantial recovery observed over two years is encouraging, but the persistence of deficits in a vulnerable minority shows why patients at higher risk should not be overlooked.” Her co-leader, Professor Hu, sketched the clinical translation: “Our results support a more targeted approach to long-term cognitive care after COVID-19. Identifying high-risk patients early could help guide monitoring and rehabilitation, while broader prevention measures such as vaccination may reduce the likelihood of progressive decline.” In practice, that means clinicians could weigh a short list of signals — age over 60, repeated infections, severe initial illness, hypertension, prolonged hospitalization and white matter lesions on imaging — to decide who needs closer cognitive surveillance, rather than placing every survivor under indefinite observation. The domain-specific pattern of recovery hands rehabilitation specialists a concrete target list as well: training that hones attention, calculation, memory encoding and retrieval, learning and executive planning, rather than generic mental stimulation.

The study is not without limitations, and its authors are careful to name them. Cognition was measured by telephone rather than through face-to-face neuropsychological testing, which captures a narrower slice of mental function and cannot fully assess language, visuospatial ability or mood. Telephone instruments also depend on a patient’s hearing and cooperation, and the informant questionnaire rests on the accuracy of a third party’s observations. The two-year horizon, long by the standards of long-COVID research, still cannot exclude deterioration or recovery beyond that window, and because the cohort consisted of hospitalized patients, the findings may not extend to the far larger population whose Omicron infections never reached a hospital ward. The researchers call for longer follow-up and comprehensive, in-person neuropsychological assessments to clarify how cognitive trajectories continue to evolve as the pandemic’s aftermath lengthens.

Even with those caveats, the study’s central message lands with force, and it is likely to reshape conversations in clinics and around kitchen tables. Post-Omicron cognitive decline — the frightening brain fog that patients describe — is largely reversible, and for the majority of survivors time appears to be an ally. Yet the study is equally clear that recovery is not universal. For older adults, the repeatedly infected, the severely ill, the hypertensive and those whose scans reveal damaged white matter, vigilance remains essential, because their decline can progress quietly while everyone else recovers. The strategy the authors propose is one of balance: reassure most patients that improvement is common, monitor the few who carry clinical or imaging risk factors, rehabilitate the specific cognitive functions that falter, and vaccinate to prevent the next infection from tipping the scales. As the world accumulates infections and reinfections, understanding which brains recover and which continue to slide may prove one of the pandemic’s most consequential open questions — and this two-year journey through the fog offers the first long, hopeful answer.

News Publication Date: 27-Aug-2026

Web References: https://doi.org/10.1002/nep3.70050

References: Wan, Y., & Hu, B. (2026). Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients. Neuroprotection. Advance online publication. https://doi.org/10.1002/nep3.70050

Understanding the cognitive sequelae of long COVID has thus far been hampered by the subtlety of brain changes and the limited sensitivity of standard neuropsychological tests. Whereas earlier animal models documented shifts in neuroinflammatory and neural plasticity markers following coronavirus infection, translating these observations to human patients has posed a challenge. Against this backdrop, the Corewell Health study took a pioneering approach by combining self-reported cognitive and emotional assessments with biochemical analyses that measure inflammation and brain adaptability — specifically focusing on blood serum markers previously linked to neural stress responses.

The study cohort was small yet carefully selected: 17 confirmed COVID-19 patients divided into two groups, 10 experiencing lingering cognitive difficulties commonly referred to as ‘brain fog,’ and seven who showed full recovery without residual symptoms. This cohort allowed researchers to draw direct comparisons under tightly controlled conditions. The data pointed to pronounced decreases in serum nerve growth factor (NGF) within the long COVID group. NGF is a crucial neurotrophic factor involved in neuronal survival, synaptic plasticity, and the brain’s capacity to reorganize in response to injury or stress. The reduction in NGF implicates impaired neural adaptability as an underpinning feature of post-COVID cognitive decline.

Simultaneously, this same group exhibited elevated levels of interleukin-10 (IL-10), an anti-inflammatory cytokine paradoxically linked to dysregulated immune responses and persistent neuroinflammation. The increase in IL-10 perhaps reflects an ongoing attempt to counteract chronic inflammation, which may nonetheless perpetuate a maladaptive state impairing cognitive function. This balance between neuroinflammation and attempted immune resolution appears disrupted in individuals suffering from long COVID, aligning with emerging theories of immunological dysfunction driving prolonged brain symptoms after viral infection.

Interestingly, conventional neuropsychological testing paradigms failed to fully capture the extent of impairment in these patients. While general cognitive test outcomes showed minimal divergence between groups, a more focused evaluation revealed that individuals with long COVID scored significantly worse on letter fluency tasks. This specific deficit points to difficulties in lexical retrieval and executive function, implicating language-related brain networks sensitive to neuroinflammatory stress and impaired synaptic connectivity. Such subtle yet impactful deficits provide new insights into why many long COVID patients describe a frustrating inability to “think clearly” despite appearing normal on routine exams.

Beyond cognitive measures, the long COVID group self-reported substantially lower quality of life, encompassing global physical health, emotional well-being, and psychological resilience. These subjective experiences underscore the pervasive impact of ongoing symptoms, which extend beyond measurable neurological dysfunction to disrupt daily functioning and mental health. The dissociation between clinical test normality and profound personal suffering highlights a critical gap in current diagnostic and therapeutic approaches, emphasizing the need for biomarker-informed evaluations.

Dr. Judith Arnetz, the study’s corresponding author and a professor emerita at Michigan State University, emphasizes the clinical implications of these findings. Early identification of individuals exhibiting biomarker signatures of impaired neuroplasticity and inflammation could enable physicians to initiate multidisciplinary treatment strategies sooner. Current clinical practice often overlooks such subtle biological disturbances, leaving patients with few options other than symptomatic relief and watchful waiting. This research advocates for integrating objective biomarkers into routine assessments, moving towards personalized care that addresses the underlying pathophysiology.

Moreover, Dr. Lawrence advocates for a comprehensive treatment model incorporating speech therapy to target language deficits, psychotherapeutic interventions to reduce chronic stress responses, and pharmacological measures aimed at alleviating fatigue and cognitive dulling. Such integrative care pathways could mitigate symptom burden, improve quality of life, and potentially restore neural function by supporting brain plasticity and immune regulation.

The study, published in PLOS One, represents an important step toward demystifying the complexities of long COVID, a syndrome afflicting tens of millions globally who remain ill years after their acute infection. The socio-economic and public health ramifications are profound, as persistent cognitive dysfunction hampers workforce participation, personal relationships, and overall societal productivity. Scientific breakthroughs that define the biological substrates of long COVID and identify actionable therapeutic targets are urgently needed to address this burgeoning crisis.

While recognizing the pilot nature and limited sample size of the study, the researchers highlight how even preliminary evidence of specific serum biomarker alterations combined with focused cognitive assessments can revolutionize our understanding of post-viral neurocognitive syndromes. Future large-scale studies are warranted to validate these findings, explore the temporal dynamics of biomarker changes, and refine diagnostic criteria for long COVID-associated cognitive impairment.

In the broader context of post-infectious neurological disorders, this research underscores the intricate interplay between the immune system and the central nervous system, challenging conventional assumptions that coronaviruses are strictly respiratory pathogens. The neuroinflammatory cascade unleashed by SARS-CoV-2 infection triggers a prolonged imbalance in neurotrophic support and immune signaling, creating a fertile ground for chronic brain dysfunction that standard tests may miss.

As the medical community grapples with the enduring consequences of the COVID-19 pandemic, studies like this pave the way for a paradigm shift — from symptom management to pathophysiology-driven therapies. The integration of neuropsychological profiling, biomarker quantification, and personalized rehabilitation could transform care delivery for millions living with the invisible yet debilitating cognitive aftermath of COVID-19.

Subject of Research: People
Article Title: Self-reported health, neuropsychological tests and biomarkers in fully recovered COVID-19 patients vs patients with post-COVID cognitive symptoms: a pilot study
News Publication Date: 15-May-2025
Image Credits: Credit: Corewell Health
Keywords: Diseases and disorders, Human health